[go: up one dir, main page]

PE20212245A1 - Composicion farmaceutica oral que comprende acido 3-[5-(2-fluorofenil)- [1,2,4]oxadiazol-3-il]-benzoico - Google Patents

Composicion farmaceutica oral que comprende acido 3-[5-(2-fluorofenil)- [1,2,4]oxadiazol-3-il]-benzoico

Info

Publication number
PE20212245A1
PE20212245A1 PE2020002230A PE2020002230A PE20212245A1 PE 20212245 A1 PE20212245 A1 PE 20212245A1 PE 2020002230 A PE2020002230 A PE 2020002230A PE 2020002230 A PE2020002230 A PE 2020002230A PE 20212245 A1 PE20212245 A1 PE 20212245A1
Authority
PE
Peru
Prior art keywords
oxadiazol
benzoic acid
fluorophenyl
pharmaceutical composition
oral pharmaceutical
Prior art date
Application number
PE2020002230A
Other languages
English (en)
Inventor
Langdon Miller
Samit Hirawat
Original Assignee
Ptc Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39102963&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20212245(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ptc Therapeutics Inc filed Critical Ptc Therapeutics Inc
Publication of PE20212245A1 publication Critical patent/PE20212245A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

La invencion se refiere a un metodo para mantener una concentracion plasmatica del acido 3-[5-(2-fluoro-fenil)-[1,2,4]oxadiazol-3-il]-benzoico o una sal, solvato o hidrato del mismo, de aproximadamente 0,1 ug/ml a 500 ug/ml o 2 ug/ml a 10 ug/ml en un paciente durante al menos aproximadamente 2, 2,5, 3, 3,5, 4, 4,5, 5, 6, 8, 12 o 24 horas o mas, que comprende en administrar una cantidad efectiva del acido 3-[5-(2-fluorofenil)-[1,2,4]oxadiazol-3-il]-benzoico o una sal farmaceuticamente aceptable, solvato o hidrato del mismo a un paciente que lo necesite una, dos o tres veces al dia en la misma dosis o a dosis en aumento.
PE2020002230A 2006-10-12 2007-10-12 Composicion farmaceutica oral que comprende acido 3-[5-(2-fluorofenil)- [1,2,4]oxadiazol-3-il]-benzoico PE20212245A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85145006P 2006-10-12 2006-10-12

Publications (1)

Publication Number Publication Date
PE20212245A1 true PE20212245A1 (es) 2021-11-24

Family

ID=39102963

Family Applications (4)

Application Number Title Priority Date Filing Date
PE2007001386A PE20080982A1 (es) 2006-10-12 2007-10-12 Metodos para dosificar un 1,2,4-oxadiazol oralmente activo para terapia de supresion de mutacion sin sentido
PE2020002230A PE20212245A1 (es) 2006-10-12 2007-10-12 Composicion farmaceutica oral que comprende acido 3-[5-(2-fluorofenil)- [1,2,4]oxadiazol-3-il]-benzoico
PE2011001559A PE20120670A1 (es) 2006-10-12 2007-10-12 Metodos para dosificar un 1, 2, 4-oxadiazol oralmente activo para terapia de supresion de mutacion sin sentido
PE2016000659A PE20160947A1 (es) 2006-10-12 2007-10-12 Composicion farmaceutica oral que comprende acido 3-[5-(2-fluorofenil)-[1,2,4]oxadiazol-3-il]benzoico

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2007001386A PE20080982A1 (es) 2006-10-12 2007-10-12 Metodos para dosificar un 1,2,4-oxadiazol oralmente activo para terapia de supresion de mutacion sin sentido

Family Applications After (2)

Application Number Title Priority Date Filing Date
PE2011001559A PE20120670A1 (es) 2006-10-12 2007-10-12 Metodos para dosificar un 1, 2, 4-oxadiazol oralmente activo para terapia de supresion de mutacion sin sentido
PE2016000659A PE20160947A1 (es) 2006-10-12 2007-10-12 Composicion farmaceutica oral que comprende acido 3-[5-(2-fluorofenil)-[1,2,4]oxadiazol-3-il]benzoico

Country Status (23)

Country Link
US (7) US9226919B2 (es)
EP (2) EP2073805B1 (es)
JP (4) JP2010506840A (es)
KR (4) KR20160128468A (es)
CN (2) CN101553226B (es)
AU (1) AU2007308067B2 (es)
BR (2) BRPI0719276A2 (es)
CA (1) CA2675518C (es)
CL (1) CL2007002923A1 (es)
DK (1) DK2073805T3 (es)
ES (1) ES2538359T3 (es)
HR (1) HRP20150590T1 (es)
IL (2) IL198147A (es)
MX (1) MX2009003909A (es)
NO (1) NO342061B1 (es)
PE (4) PE20080982A1 (es)
PL (1) PL2073805T3 (es)
PT (1) PT2073805E (es)
RS (1) RS54025B1 (es)
RU (1) RU2462247C2 (es)
SI (1) SI2073805T1 (es)
TW (1) TWI405570B (es)
WO (1) WO2008045566A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2887054T3 (es) 2003-04-11 2021-12-21 Ptc Therapeutics Inc Compuesto de ácido 1,2,4-oxadiazol benzoico y su uso para la supresión sin sentido y el tratamiento de enfermedades
IN2014CN04406A (es) 2006-03-30 2015-09-04 Ptc Therapeutics Inc
RU2462247C2 (ru) 2006-10-12 2012-09-27 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способы дозирования перорально активного 1,2,4-оксадиазола для терапии, подавляющей нонсенс-мутацию
CA2771403C (en) 2009-08-19 2015-02-24 Eisai R&D Management Co. Ltd. Quinoline derivative-containing pharmaceutical composition
EP2714937B1 (en) 2011-06-03 2018-11-14 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
WO2015134711A1 (en) * 2014-03-06 2015-09-11 Ptc Therapeutics, Inc. Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid
LT3524595T (lt) 2014-08-28 2022-09-26 Eisai R&D Management Co., Ltd. Aukšto grynumo chinolino darinys ir jo gamybos būdas
US20180028662A1 (en) * 2015-02-25 2018-02-01 Eisai R&D Management Co., Ltd. Method for Suppressing Bitterness of Quinoline Derivative
MX373231B (es) 2015-06-16 2020-05-08 Eisai R&D Man Co Ltd Agente anticancerigeno.
CN108135894B (zh) 2015-08-20 2021-02-19 卫材R&D管理有限公司 肿瘤治疗剂
CN108348527A (zh) 2015-10-30 2018-07-31 Ptc医疗公司 用于治疗癫痫的方法
JP6581320B2 (ja) 2017-02-08 2019-09-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療用医薬組成物
RU2019134940A (ru) 2017-05-16 2021-06-16 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Лечение гепатоцеллюлярной карциномы
TWI801438B (zh) 2017-10-19 2023-05-11 中國大陸商軒竹（北京）醫藥科技有限公司 抗菌胺基糖苷類似物之合成
US11203578B2 (en) 2017-11-23 2021-12-21 Universita'degli Studi Dipalermo Oxadiazole derivatives for the treatment of genetic diseases due to nonsense mutations
KR20210151131A (ko) * 2019-04-10 2021-12-13 피티씨 테라퓨틱스, 인크. 소아 환자에서 넌센스 돌연변이 매개된 뒤센 근이영양증의 치료 방법
WO2022177267A1 (ko) * 2021-02-16 2022-08-25 라이보텍(주) 넌센스-매개 mrna 분해를 억제하기 위한 화합물
KR102378381B1 (ko) * 2021-08-23 2022-03-24 라이보텍(주) 넌센스-매개 mRNA 분해를 억제하기 위한 화합물
WO2022241030A1 (en) * 2021-05-11 2022-11-17 Regenxbio Inc. Treatment of duchenne muscular dystrophy and combinations thereof
KR102665711B1 (ko) * 2021-12-21 2024-05-14 재단법인 아산사회복지재단 Ras 활성도를 이용한 신경섬유종증 치료제에 대한 감수성 예측용 바이오마커 조성물 및 Ras 활성 억제제를 포함하는 신경섬유종증 예방 또는 치료용 약학적 조성물
CN119638642A (zh) * 2023-12-12 2025-03-18 暨南大学 双环类化合物及其药物组合物和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660753B2 (en) 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
AU2002313633B2 (en) 2001-06-08 2007-03-01 Cytovia, Inc. Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs
MY151199A (en) 2001-11-02 2014-04-30 Rigel Pharmaceuticals Inc Substituted diphenyl heterocycles useful for treating hcv infection
JP2006506340A (ja) 2002-08-09 2006-02-23 アストラゼネカ アクチボラグ 代謝調節型グルタミン酸受容体５のモジュレーターとしてのオキサジアゾール
GB0303503D0 (en) 2003-02-14 2003-03-19 Novartis Ag Organic compounds
ES2887054T3 (es) * 2003-04-11 2021-12-21 Ptc Therapeutics Inc Compuesto de ácido 1,2,4-oxadiazol benzoico y su uso para la supresión sin sentido y el tratamiento de enfermedades
WO2004110351A2 (en) 2003-05-14 2004-12-23 Anadys Pharmaceuticals, Inc. Heterocyclic compounds for treating hepatitis c virus
CN1905856A (zh) * 2003-12-23 2007-01-31 阿尔扎公司 用于增加受控递送的药物组合物的溶解度的方法和剂型
DK1874306T3 (da) * 2005-04-08 2012-10-01 Ptc Therapeutics Inc Sammensætninger af en oralt aktiv 1,2,4-oxadiazol til nonsens-mutationssuppressionsterapi
US20070010553A1 (en) 2005-07-01 2007-01-11 Astrazeneca Ab New use
BRPI0716996B8 (pt) 2006-09-08 2021-05-25 Ptc Therapeutics Inc processo para preparar um composto
US7863456B2 (en) 2006-09-25 2011-01-04 Ptc Therapeutics, Inc. Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-YL]-benzoic acid
RU2462247C2 (ru) * 2006-10-12 2012-09-27 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способы дозирования перорально активного 1,2,4-оксадиазола для терапии, подавляющей нонсенс-мутацию

Also Published As

Publication number Publication date
US10849885B2 (en) 2020-12-01
RU2009117590A (ru) 2010-11-20
US20170304275A1 (en) 2017-10-26
SI2073805T1 (sl) 2015-10-30
NO20091826L (no) 2009-07-08
PE20160947A1 (es) 2016-09-26
CN101553226B (zh) 2015-05-13
CN103211766A (zh) 2013-07-24
PE20080982A1 (es) 2008-07-19
JP2017081946A (ja) 2017-05-18
BR122019020961B8 (pt) 2021-07-27
EP2460520B1 (en) 2015-09-30
MX2009003909A (es) 2009-05-25
JP2014058533A (ja) 2014-04-03
HRP20150590T1 (hr) 2015-07-03
JP6129713B2 (ja) 2017-05-17
IL198147A (en) 2016-02-29
KR20170100072A (ko) 2017-09-01
US9522137B2 (en) 2016-12-20
BRPI0719276A2 (pt) 2014-04-29
HK1136214A1 (en) 2010-06-25
ES2538359T3 (es) 2015-06-19
PL2073805T3 (pl) 2015-08-31
CN103211766B (zh) 2015-03-11
CN101553226A (zh) 2009-10-07
US20180140583A1 (en) 2018-05-24
KR20160128468A (ko) 2016-11-07
US9226919B2 (en) 2016-01-05
TWI405570B (zh) 2013-08-21
HK1170690A1 (en) 2013-03-08
AU2007308067B2 (en) 2013-05-30
CA2675518C (en) 2017-11-14
KR20090074231A (ko) 2009-07-06
AU2007308067A1 (en) 2008-04-17
EP2073805A1 (en) 2009-07-01
IL236519A (en) 2017-03-30
CL2007002923A1 (es) 2008-06-06
IL198147A0 (en) 2009-12-24
EP2460520A1 (en) 2012-06-06
US9877952B2 (en) 2018-01-30
PT2073805E (pt) 2015-07-13
WO2008045566B1 (en) 2008-06-19
US9737513B2 (en) 2017-08-22
US20210038572A1 (en) 2021-02-11
KR20150064244A (ko) 2015-06-10
US20170049752A1 (en) 2017-02-23
JP2016029078A (ja) 2016-03-03
TW200820968A (en) 2008-05-16
KR101758341B1 (ko) 2017-07-14
IL236519A0 (en) 2015-02-26
JP6333227B2 (ja) 2018-05-30
JP2010506840A (ja) 2010-03-04
RU2462247C2 (ru) 2012-09-27
US20190099405A1 (en) 2019-04-04
US20080114039A1 (en) 2008-05-15
BR122019020961B1 (pt) 2021-03-09
WO2008045566A1 (en) 2008-04-17
US10172836B2 (en) 2019-01-08
RS54025B1 (sr) 2015-10-30
NO342061B1 (no) 2018-03-19
CA2675518A1 (en) 2008-04-17
DK2073805T3 (da) 2015-06-15
US20160101087A1 (en) 2016-04-14
EP2073805B1 (en) 2015-03-04
PE20120670A1 (es) 2012-06-01

Similar Documents

Publication Publication Date Title
PE20212245A1 (es) Composicion farmaceutica oral que comprende acido 3-[5-(2-fluorofenil)- [1,2,4]oxadiazol-3-il]-benzoico
CY1119001T1 (el) Ενωσεις 1,2,4-οξαδιαζολο βενζοϊκου οξεος και χρηση αυτων για ανευ νοηματος καταστολη και τη θεραπεια ασθενειας
CL2011001178A1 (es) Uso de (r)-7-cloro-niquinuclidin-3-1l)senzo[b]tiofen0-2-carboxamida o una sal de la misma o una composicion farmaceutica que la comprende para preparar un medicamento util para mejorar la cognicion en un paciente que sufre de alzheimer o esquizofrenia.
MX2015017307A (es) Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington.
CY1114215T1 (el) Φαρμακευτικες συνθεσεις διαλυματος για υπο πιεση εισπνευστηρες μετρουμενης δοσης
MX2010005342A (es) Compuestos indola y metodos para tratar el dolor visceral.
UA107578C2 (uk) Комбінована терапія при лікуванні діабету
NO20091938L (no) 7,8-dihydro-1,6-naftyridin-5(6H)-oner og relaterte bicykliske forbindelser som inhibitorer av dipeptidyl-peptidaser IV og metoder
EA200971041A1 (ru) Новые пептидные ингибиторы репликации вируса гепатита с
WO2013003629A3 (en) Methods and compositions for inhibition of bone resorption
EA200800413A1 (ru) Новые макроциклические ингибиторы репликации вируса гепатита с
MX346186B (es) Inhibidores de proteina cinasas.
MX2010004501A (es) Inhibidor de la proteina de activacion de 5-lipoxigenasa (plap).
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
PH12021552930A1 (en) 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
DE602004008959D1 (de) Benzoäbüä1,4üdioxepinderivate
RU2014141893A (ru) Применение производной пиразола в лечении острых приступов хронической обструктивной болезни легких
NO20065061L (no) Benzoksazin for behandling av sykdommer i luftveiene
RU2015141360A (ru) Ингибиторы тирозинкиназы брутона
HRP20050103A2 (en) N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b secretion
WO2007003330A3 (de) Pharmazeutische darreichungsformen enthaltend eine wirkstoffkombination von nifedipin und/oder nisoldipin und einem angiotensin-ii antagonisten
BR112012020060B8 (pt) uso de n-((1-((4-hidroxitetrahidro-2h-piran-4-il)metil)piperidin-4-il)metil)-3-isopropil-2-oxo-2,3-dihidro-1h-benzo[d]imidazol-1-carboxamida para tratar doença de alzheimer e demência
AR059838A1 (es) Formulaciones para dosis estabilizantes de estatina
BRPI0512241A (pt) inalador utilizando casulos
KR102707515B1 (ko) 류머티스 관절염의 치료를 위한 조성물 및 방법